Tuesday, December 28, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including salesforce.com, inc. (CRM), Intuit Inc. (INTU), and Bristol-Myers Squibb Company (BMY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of salesforce have underperformed the Zacks Computer Software industry over the past year (+16.1% vs. +41.9%), however, things seem to be improving for it. The Zacks analyst believes that salesforce has been benefiting from a robust demand environment on the back of the ongoing digital transformation.

The rapid adoption of its cloud-based solutions has also been driving demand for its products. CRM’s sustained focus on introducing more products aligned with customer needs is another positive. The recent acquisition of Slack is likely to position CRM as a leader in enterprise team collaboration solution space. Stiff competition and unfavorable currency fluctuations, however, remain as major concerns for salesforce.

(You can read the full research report on salesforce here >>>)

Intuit shares have gained +72.7% in the year to date period against the Zacks Computer Software industry’s gain of +42.3%. The Zacks analyst believes that Intuit has been benefiting from strong momentum in online ecosystem revenues as well as professional tax revenues.

The TurboTax Live offering is also driving growth in the Consumer tax business. INTU’s strategy of shifting its business to cloud-based subscription model is likely to generate stable revenues in the long run. Pandemic related global lockdowns, higher expenses due to increased investments in marketing and engineering team are some of the major concerns though.

(You can read the full research report on Intuit here >>>)

Shares of Bristol-Myers have gained +3.6% in the last three months against the Zacks Biomedical and Genetics industry’s loss of -14.4%. The Zacks analyst believes that strong sales of drugs like Opdivo, Revlimid and Eliquis are likely to continue driving BMY’s top line. Bristol-Myers’ efforts to develop its pipeline are also encouraging.

The label expansion of Opdivo into indications of lung cancer, renal cancer and gastric cancer has been boosting sales. The approval of new drugs like Reblozyl will add a new stream of revenues, which should also boost growth. Generic competition as well as pipeline setbacks, however, remain as major threats.

(You can read the full research report on Bristol-Myers here >>>)

Other noteworthy reports we are featuring today include Chevron Corporation (CVX), QUALCOMM Incorporated (QCOM) and Lockheed Martin Corporation (LMT).

Sheraz Mian

Director of Research

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>